This paper is in the following e-collection/theme issue:

#xInfectiousDiseases (28) JMIR Theme Issue: COVID-19 Special Issue (2450) #xPublicandGlobalHealth (34)

Published on in Vol 2, No 3 (2021): Jul-Sep

Preprints (earlier versions) of this paper are available at https://www.medrxiv.org/content/10.1101/2021.04.09.21255219v1, first published .
Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

Authors of this article:

Mark Jarrett1 Author Orcid Image ;   Warren Licht1 Author Orcid Image ;   Kevin Bock1 Author Orcid Image ;   Zenobia Brown1 Author Orcid Image ;   Jamie Hirsch1 Author Orcid Image ;   Kevin Coppa2 Author Orcid Image ;   Rajdeep Brar1 Author Orcid Image ;   Stephen Bello2 Author Orcid Image ;   Ira Nash1 Author Orcid Image
Article Authors Cited by (4) Tweetations (4) Metrics

Mark Jarrett   1 * , MBA, MD ;   Warren Licht   1 * , MD ;   Kevin Bock   1 * , MHCDS, MD ;   Zenobia Brown   1 * , MPH, MD ;   Jamie Hirsch   1 * , MA, MSB, MD ;   Kevin Coppa   2 * , BSc ;   Rajdeep Brar   1 * , MD ;   Stephen Bello   2 * , PA, MHCDS ;   Ira Nash   1 * , MD

1 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, United States

2 Northwell Health, New Hyde Park, NY, United States

*all authors contributed equally

Corresponding Author:

  • Mark Jarrett, MBA, MD
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • Hofstra University
  • 500 Hofstra University
  • Hempstead, NY, 11549
  • United States
  • Phone: 1 516-463-7516
  • Email: mjarrett@northwell.edu